Preliminary anti-cancer photodynamic therapeutic in vitro studies with mixed-metal binuclear ruthenium(ii)–vanadium(iv) complexes
作者:Alvin A. Holder、Patrick Taylor、Anthony R. Magnusen、Erick T. Moffett、Kyle Meyer、Yiling Hong、Stuart E. Ramsdale、Michelle Gordon、Javelyn Stubbs、Luke A. Seymour、Dhiraj Acharya、Ralph T. Weber、Paul F. Smith、G. Charles Dismukes、Ping Ji、Laura Menocal、Fengwei Bai、Jennie L. Williams、Donald M. Cropek、William L. Jarrett
DOI:10.1039/c3dt50547b
日期:——
We report the synthesis and characterisation of mixed-metal binuclear ruthenium(II)–vanadium(IV) complexes, which were used as potential photodynamic therapeutic agents for melanoma cell growth inhibition. The novel complexes, [Ru(pbt)2(phen2DTT)](PF6)2·1.5H2O 1 (where phen2DTT = 1,4-bis(1,10-phenanthrolin-5-ylsulfanyl)butane-2,3-diol and pbt = 2-(2′-pyridyl)benzothiazole) and [Ru(pbt)2(tpphz)](PF6)2·3H2O
我们报道了混合金属双核钌( II )-钒( IV )络合物的合成和表征,该络合物被用作抑制黑色素瘤细胞生长的潜在光动力治疗剂。新型配合物 [Ru(pbt) 2 (phen 2 DTT)](PF 6 ) 2 ·1.5H 2 O 1(其中 phen 2 DTT =1,4-双(1,10-菲咯啉-5-基硫基)丁-2,3-二醇且 pbt = 2-(2′-吡啶基)苯并噻唑) 和 [Ru(pbt) 2 (tpphz)](PF 6 ) 2 ·3H 2 O 2(其中 tpphz = 四吡啶基[3,2- a :2′,3 '- c :3'',2''- h :2''',3'''- j ]吩嗪)被合成并表征。化合物1与[VO(sal- L -tryp)(H 2 O)](其中sal- L -tryp= N-水杨基-L-色氨酸)反应生成[Ru(pbt) 2 (phen 2 DTT)VO (sal- L-胰蛋白酶)](PF